ArticleBiomaterials2016
Treatment of hind limb ischemia using angiogenic peptide nanofibers.
Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 106 citations in OpenAlex.
- Article
- Tunable regional targeting of self-assembling peptide nanomaterials in acute myocardial infarction.Advanced nanobiomed research · 2026Article
- Programming angiogenesis with tunable assemblies of multifunctional peptides.Science advances · 2026Article
- Exosomes derived from ADSCs suppress the fibrosis process of derma in secondary lymphedema.Scientific reports · 2026Article
- Anti-swelling and self-activating artificial proteoglycan assemblies as cartilaginous implant for post-microfracture healing.Nature communications · 2025Article
- Strategies for the vascular patterning of engineered tissues for organ repair.Nature biomedical engineering · 2025Review
- Is Laser Doppler Perfusion Imaging Truly a "Gold Standard" for Preclinical Peripheral Artery Disease Research?JACC. Basic to translational science · 2025Article
- Structural Consequences of Introducing Bioactive Domains to Designer β-Sheet Peptide Self-Assemblies.Biomacromolecules · 2024Article
- Injectable Peptide Hydrogels Loaded with Murine Embryonic Stem Cells Relieve IschemiaBiomacromolecules · 2024Article
- Antiviral fibrils of self-assembled peptides with tunable compositions.Nature communications · 2024Article
- Self-Assembling Peptides with Insulin-Like Growth Factor Mimicry.ACS applied materials & interfaces · 2024Article
- Growth factor free, peptide-functionalized gelatin hydrogel promotes arteriogenesis and attenuates tissue damage in a murine model of critical limb ischemia.Biomaterials · 2023Article
- Review on Additives in Hydrogels for 3D Bioprinting of Regenerative Medicine: From Mechanism to Methodology.Pharmaceutics · 2023Review
- Synthetic extracellular matrices with function-encoding peptides.Nature reviews bioengineering · 2023Review
- Self-assembling Molecular Medicine for the Subacute Phase of Ischemic Stroke.Neurochemical research · 2022Review
- iPSC-derived cranial neural crest-like cells can replicate dental pulp tissue with the aid of angiogenic hydrogel.Bioactive materials · 2022Article
- Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease.Advanced pharmaceutical bulletin · 2022Review
- Angiogenic Hydrogels to Accelerate Early Wound Healing.Macromolecular bioscience · 2022Article
- Delivery of VEGF and delta-like 4 to synergistically regenerate capillaries and arterioles in ischemic limbs.Acta biomaterialia · 2022Article
- Application of periostin peptide-decorated self-assembled protein cage nanoparticles for therapeutic angiogenesis.BMB reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
For a proangiogenic therapy to be successful, it must promote the development of mature vasculature for rapid reperfusion of ischemic tissue. Whole growth factor, stem cell, and gene therapies have yet to achieve the clinical success needed to become FDA-approved revascularization therapies. Herein, we characterize a biodegradable peptide-based scaffold engineered to mimic VEGF and self-assemble into a nanofibrous, thixotropic hydrogel, SLanc. We found that this injectable hydrogel was rapidly infiltrated by host cells and could be degraded while promoting the generation of neovessels. In mice with induced hind limb ischemia, this synthetic peptide scaffold promoted angiogenesis and ischemic tissue recovery, as shown by Doppler-quantified limb perfusion and a treadmill endurance test. Thirteen-month-old mice showed significant recovery within 7 days of treatment. Biodistribution studies in healthy mice showed that the hydrogel is safe when administered intramuscularly, subcutaneously, or intravenously. These preclinical studies help establish the efficacy of this treatment for peripheral artery disease due to diminished microvascular perfusion, a necessary step before clinical translation. This peptide-based approach eliminates the need for cell transplantation or viral gene transfection (therapies currently being assessed in clinical trials) and could be a more effective regenerative medicine approach to microvascular tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.